178 related articles for article (PubMed ID: 21998350)
1. The seduction of biomarkers in the practice of medicine and the tyranny of power in the drug approval process: lessons from niacin.
Lehmann DF; Sitar DS
J Clin Pharmacol; 2011 Nov; 51(11):1496-8. PubMed ID: 21998350
[No Abstract] [Full Text] [Related]
2. Biomarker qualification pilot process at the US Food and Drug Administration.
Goodsaid F; Frueh F
AAPS J; 2007 Mar; 9(1):E105-8. PubMed ID: 17408233
[TBL] [Abstract][Full Text] [Related]
3. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
4. Turning a blind eye.
Nat Med; 2008 Jan; 14(1):1. PubMed ID: 18180702
[No Abstract] [Full Text] [Related]
5. A stepwise approach to evaluating new drug therapy.
Wessell A; Blair M
JAAPA; 2001 Nov; 14(11):10-1. PubMed ID: 11766421
[No Abstract] [Full Text] [Related]
6. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
Peck CC; Rubin DB; Sheiner LB
Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
[No Abstract] [Full Text] [Related]
7. Paediatric clinical trials: redressing the imbalance.
Schreiner MS
Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
[No Abstract] [Full Text] [Related]
8. "Getting the dose right": facts, a blueprint, and encouragements.
Peck CC; Cross JT
Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
[No Abstract] [Full Text] [Related]
9. Drug testing. Regulators talk up plans for drug biomarkers ..
Couzin J
Science; 2004 Nov; 306(5699):1119. PubMed ID: 15539576
[No Abstract] [Full Text] [Related]
10. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
11. Drug markers questioned.
Ledford H
Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
[No Abstract] [Full Text] [Related]
12. Strong medicine.
Wadman M
Nat Med; 2005 May; 11(5):465-6. PubMed ID: 15875044
[No Abstract] [Full Text] [Related]
13. Pediatric drug studies. Protecting pint-sized patients.
Nordenberg T
FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
[No Abstract] [Full Text] [Related]
14. From laboratory to medicine cabinet.
Caring; 1992 Nov; 11(11):16-20. PubMed ID: 10121248
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics. Going from genome to pill.
Service RF
Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
[No Abstract] [Full Text] [Related]
16. Disease models.
Gobburu J
Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
[No Abstract] [Full Text] [Related]
17. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
18. Benefit the patient, manage the risk: a system goal.
Califf RM
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777
[No Abstract] [Full Text] [Related]
19. Errors in 'Trials and error'.
Miller DD
Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048
[No Abstract] [Full Text] [Related]
20. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]